Moleculin announces COVID-19 drug collaboration
Moleculin Biotech has inked an agreement with the University of Campinas in São Paulo, Brazil, to collaborate on researching the antiviral capabilities of WP1122, its COVID-19 drug candidate.
Takeda expands COVID-19 vaccine supply with Moderna, Japan
Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.
Emulate to provide FDA with 'lung chips' to evaluate COVID-19 vaccines
Emulate has entered a cooperative research and development agreement with the U.S. Food and Drug Administration (FDA) to enable multiple studies to evaluate COVID-19 vaccines and understand immune responses against SARS-CoV-2.
Qualigen to advance COVID-19 DNA aptamer drug candidate
The U.S. Food and Drug Administration has provided written feedback to Qualigen Therapeutics on the company's plan to advance its COVID-19 DNA aptamer drug candidate to clinical trials.
Eli Lilly to supply U.S. with 300,000 doses of anti-SARS-CoV-2 antibody
Eli Lilly has entered an initial agreement with the U.S. government to supply 300,000 vials of LY-CoV555 (bamlanivimab), the company's investigational neutralizing antibody to fight SARS-CoV-2 infection, for $375 million.
GCAR begins COVID-19 clinical trials
The Global Coalition for Adaptive Research (GCAR) said that the first patient has been enrolled in an adaptive multicenter clinical trial to test interventions for hospitalized COVID-19 patients.
Nektar plans clinical trial for COVID-19 treatment
Nektar Therapeutics has received clearance from the U.S. Food and Drug Administration for an investigational new drug application for its interleukin-2 pathway agent NKTR-214 (Bempegaldesleukin) for evaluation in a phase IB clinical study in adult patients with mild COVID-19 infection.
New COVID-19 immunogen could help with early diagnosis
A new assay that detects the unique SARS-CoV-2 orf8 protein in the sera of COVID-19 patients in the early stage of the infection is a strategic step in controlling the COVID-19 pandemic, according to research published online October 20 in mBio.  Discuss
Who should get the 1st COVID-19 vaccines?
Once a vaccine for SARS-CoV-2 is approved by the U.S. Food and Drug Administration to be administered to the public, who should receive it first, given that its supply will be initially limited? A new perspective published in Science on October 21 fleshes out different COVID-19 vaccine distribution strategies that would ensure optimal protection from the disease under conditions of vaccine scarcity.  Discuss
HiFiBiO advances trial of SARS-CoV-2 neutralizing antibodies
HiFiBiO Therapeutics has completed the first cohort of a phase I clinical study evaluating a SARS-CoV-2 neutralizing antibody.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter